Metabolic Brain Disease

, Volume 27, Issue 4, pp 443–451 | Cite as

Effects of statins and cholesterol on memory functions in mice

  • Ravindra M. Ghodke
  • Nagesh Tour
  • Kshama Devi
Original Paper


Studies on influence of lipid lowering therapies have generated wide controversial results on the role of cholesterol on memory function. However recent studies revealed that cholesterol lowering treatment substantially reduce the risk of dementia. The objectives of this study were to analyze the effect of statins on memory function and to establish the relationship between increase/decrease in cholesterol synthesis, total cholesterol level and memory function in animals. We examined the relationship between biosynthesis of cholesterol and memory function using two statins (lipophilic simvastatin and hydrophilic pravastatin) and high cholesterol diet in mice for 15 days and 4 months. Memory performance was evaluated with two different behavioral tests and various biochemical parameters such as serum cholesterol, whole brain cholesterol, brain 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) activity and brain acetylcholine esterase (AChE) activity. We found that statin treatment for 4 months, but not for 15 days, showed significant improvement in memory function whereas high cholesterol diet showed significant impairment of memory. However long-term statin treatment showed significant decrease in serum cholesterol level as well as brain AChE level. Moreover high cholesterol diet showed significant decrease in memory function with an increase in serum cholesterol level as well as brain AChE level. There is no direct correlation between brain cholesterol level, as well as HMG-CoA activity with memory function regulation. However there is definite link between plasma cholesterol level and AChE level. A long-standing plasma cholesterol alteration may be essential to regulate memory function which in turn might be mediated through AChE modulated pathway.


Brain cholesterol Statins AChE Memory function 


  1. Andersson M, Elmberger PG, Edlund C, Kristensson K, Dallner G (1990) Rates of cholesterol, ubiquinone, dolichol and dolichyl-P biosynthesis in rat brain slices. FEBS lett 269:15–18PubMedCrossRefGoogle Scholar
  2. Bjorkhelm I, Lutjohann D, Breuer O, Sakinis A, Wennmalm (1997) Importance of a novel oxidative mechanism for elimination of brain cholesterol. J Biol Chem 272:30178–30184CrossRefGoogle Scholar
  3. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA (1991) Expanded clinical evaluation of lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151:43–49PubMedCrossRefGoogle Scholar
  4. Butterfield DA, Barone E, Mancuso C (2011) Cholesterol independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 64:180–186PubMedCrossRefGoogle Scholar
  5. Cibickova L (2011) Statins and their influence on brain cholesterol. J Clin Lipidol 5:373–379PubMedCrossRefGoogle Scholar
  6. Cibickova L, Palicka V, Cibicek N, Cermakova E, Micuda S, Bartosova L (2007) Differential effects of statins and alendronate on cholinesterase in serum and brain of rats. Physiol Res 56:765–770PubMedGoogle Scholar
  7. Cole SL, Vassar R (2006) Isoprenoids and Alzheimer’s disease: a complex relationship. Neurobiol Dis 22:209–222PubMedCrossRefGoogle Scholar
  8. Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12:105–112PubMedCrossRefGoogle Scholar
  9. Ellman GL, Courtney KD, Andres V, Feathersome RM (1961) A new and rapid colorimetric determination of Acetylcholinesterase activity. Biochem Pharmacol 7:88–95PubMedCrossRefGoogle Scholar
  10. Franke C, Noldner M, Abdel-Kader R, Johnson-Anuna LN, Wood WG, Muller WE (2007) Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis 25:438–445PubMedCrossRefGoogle Scholar
  11. Henderson VW, Guthrie JR, Dennerstein L (2003) Serum lipids and memory in a population base cohort of middle age women. J Neurol Neurosurg Psychiat 74:1530–1535PubMedCrossRefGoogle Scholar
  12. Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K (2004) Plasma levels β-Amyloid(1–40), β-Amyloid(1–42), and total β-Amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61:333–337PubMedCrossRefGoogle Scholar
  13. Itoh J, Nabeshima T, Kameyama T (1991) Utility of elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eup J Pharmacol 194:71–76CrossRefGoogle Scholar
  14. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627–1631PubMedCrossRefGoogle Scholar
  15. Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T (2005) Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312:786–793PubMedCrossRefGoogle Scholar
  16. Kabara JJ (1973) A critical review of brain cholesterol metabolism. Prog Brain Res 40:363–382PubMedCrossRefGoogle Scholar
  17. Kirsch C, Eckert GP, Mueller WE (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharm 65:843–856PubMedCrossRefGoogle Scholar
  18. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M (1990) Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochem Biophys Acta 1045:115–120PubMedCrossRefGoogle Scholar
  19. Kotti TJ, Ramirez DMO, Pfeiffer BE, Huber KM, Russell DW (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. PNAS 103:3869–3874PubMedCrossRefGoogle Scholar
  20. Lane MR, Farlow MR (2005) Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer’s disease. J Lipid Res 46:949–968PubMedCrossRefGoogle Scholar
  21. Lutjohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal B, Thelen K (2004) High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69:431–438PubMedCrossRefGoogle Scholar
  22. McGirt MJ, Lynch JR, Parra A, Sheng H, Pearlstein RD, Laskowitz TL (2002) Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 33:2950–2956PubMedCrossRefGoogle Scholar
  23. Nelson TJ, Alkon DL (2005) Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem Soc Trans 33:1033–1036PubMedCrossRefGoogle Scholar
  24. Parsons RB, Price GC, Farrant JK, Subramaniam D, Sheikh JA, Austen BM (2006) Statin inhibits the dimerization of β-secretase via both isoprenoid- and cholesterol-mediated mechanisms. Biochem J 399:205–214PubMedCrossRefGoogle Scholar
  25. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S (2005) Modulation of statin-activated shedding of Alzheimer APP cetodomain by ROCK. PLoS Med 2:18CrossRefGoogle Scholar
  26. Pereira CMF, Fonseca AC, Resende R, Oliveira CR (2010) Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol 223:282–293PubMedCrossRefGoogle Scholar
  27. Quevedo J, Vianna MRM, Roesler R, de-Paris F, Izquierdo I, Rose SPR (1999) Two time windows of anisomycin-induced amnesia for inhibitory avoidance training by pretraining but not pre-exposure to the task apparatus. Learn Mem 6:600–607PubMedCrossRefGoogle Scholar
  28. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Bryant TT (2001) A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 8:890–899PubMedCrossRefGoogle Scholar
  29. Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, Andersson U (2006) Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 316:1146–1152PubMedCrossRefGoogle Scholar
  30. Tsuji A, Saheki A, Tamai I, Terasaki T (1993) Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor at the blood–brain barrier. J Pharmacol Exp Ther 267:1085–1090PubMedGoogle Scholar
  31. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (2003) Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23:871–880PubMedCrossRefGoogle Scholar
  32. Wang Q, Ting WL, Yang H, Wong TH (2005) High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br J Pharm 144:933–939CrossRefGoogle Scholar
  33. Wang H, Lynch JR, Song P, Yang HJ, Yates RB, Mace B (2007) Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol 206:59–69PubMedCrossRefGoogle Scholar
  34. Yan-qiang L, Tian-rong X, Xian-yu L, Qing J, Ying J, Hui-di Y (2007) Memory performance of hypercholesterolemic mice in respose to treatment with soy isoflavones. Neurosci Res 57:544–549CrossRefGoogle Scholar
  35. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23:11104–11111PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Al-ameen College of PharmacyBangloreIndia
  2. 2.K. T. Patil College of PharmacyOsmanabadIndia

Personalised recommendations